Insight

$Rahul Banerjee: Fascinating small Ph2 trial on relapsed or refractory multiple myeloma$

Jul 3, 2024, 02:35

Rahul Banerjee: Fascinating small Ph2 trial on relapsed or refractory multiple myeloma

Rahul Banerjee, Assistant Professor at UW Medicine, made the following post on X:

“Absolutely abscopal responses …. in myeloma??

Fascinating small Ph2 trial in The Lancet Haematology by Khan Sagar Lonial et al:

Pembro q3wk + 1 Fx RT to EMD sites… 7/25 responders, inc. 2 CRs. Better than I might’ve guessed for pembro monoTx in multiple myeloma.”

$Rahul Banerjee: Fascinating small Ph2 trial on relapsed or refractory multiple myeloma$

Read further.
Source: Rahul Banerjee/X

abscopal responses Assistant professor cancer complete response EMD sites immunotherapy Khan Sagar Lonial multiple myeloma Myeloma OncoDaily Oncology oncology research pembrolizumab phase 2 trial radiotherapy Rahul Banerjee The Lancet Haematology UW Medicine

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage